

RECEIVED

JUL 05 1995

Central Medical Library
CATHOLIC MEDICAL CENTER



salbutamol + ipratropium bromide

COMBIVENT

metered aerosol

A Logical Combination in COPD

Salbutamol + ipratropium bromide in a single metered dose inhaler

Prescribing information Combivent Metered Aerosol containing 200 doses, each delivering ipratropium bromide (anticholinergic bronchodilator) 20 micrograms and salbutamol (β_2 -adrenergic agonist) 100 micrograms. **Indication:** treatment of bronchospasm associated with chronic obstructive pulmonary disease in patients who require regular treatment with both ipratropium and salbutamol. **Dosage:** Adults only: two puffs four times a day. **Contra-indication:** known hypersensitivity to any of the components or to atropine or its derivatives. **Precautions:** cardiac disorders; hyperthyroidism; diabetes mellitus; co-prescription with β -blockers, corticosteroids, xanthine derivatives, other β -agonists or anticholinergics; pregnancy, especially the first trimester, and breast feeding. Potentially

serious hypokalaemia may result from β_2 -agonist therapy. Advise patient to seek medical advice in the event of acute, rapidly worsening dyspnoea or if response lessens; do not spray into the eye. **Side-effects:** tremor and nervousness may occur; tachycardia, dizziness, palpitations, headache, local reactions such as dryness of the mouth are less frequent; urinary retention has been reported rarely. As with other bronchodilators, cough and, very rarely, paradoxical bronchoconstriction have been observed. **Basic NHS price:** 10ml vial complete with mouthpiece UK £6.00, POM. PL 0015 0191. PA 7 52:1 **Product Licence and Authorisation Holder:** Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, RG12 8YS. For full prescribing information please see data sheet.



**Boehringer
Ingelheim**



WANT TO GET YOUR PAPERS PUBLISHED?

Read this first!

How to Write a Paper tells you all you need to know to get a paper accepted for publication. Edited by George M Hall, with contributions from editors of international journals such as the *BMJ*, *British Journal of Anaesthesia* and *Cardiovascular Research*, it explains in refreshingly direct style what journal editors are looking for in a good paper.

Contents cover:

- How to approach the various sections of a scientific paper – abstract, introduction, methods, results, discussion, and references
- How to write case reports and reviews
- The publishing process – the role of the editor, assessor, publisher, house style and electronic publishing



ISBN 07279 0822 7 126pp 1994
UK £8.95; Overseas £11.00
BMA Members: £8.45; Overseas £10.50

Available from: BMJ Publishing Group, PO Box 295, London WC1H 9TE (tel: 071 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House.

Beclazone *Easi-Breathe* Inhaler

Beclomethasone Dipropionate BP

(Please refer to full data sheet before prescribing)

■ **Uses** Provides automatic actuation of inhaler with inspiration. For the management bronchial asthma especially in patients inadequately controlled by bronchodilators and sodium cromoglycate.

■ **Dosage and Administration** Use regularly.
Adults, Beclazone 50 and 100 Easi-Breathe Inhalers; 100 microgram three or four times daily.
Beclazone 250 Easi-Breathe Inhaler; 500 microgram twice a day or 250 microgram four times a day.
Elderly, no dose adjustment necessary, including patients with renal or hepatic impairment.
Children, Beclazone 50 and 100 Easi-Breathe Inhalers; 50 to 100 microgram two to four times daily. **Beclazone 250 Easi-Breathe Inhaler** is not indicated for use in children.

■ **Contra-Indications** Hypersensitivity to the ingredient

■ **Precautions** Patients should be instructed in the correct use of inhalers. May induce systemic cortico-steroid effects (with reduction in plasma cortisol levels) and adrenal suppression (above 2000 microgram daily) – monitor adrenal function and provide systemic steroids in appropriate cases of stress. Caution in patients with history of, or active pulmonary tuberculosis. Avoid sudden cessation of treatment.

■ **Pregnancy/Lactation** Use inhalers only if the potential benefit outweighs the risk.

■ **Side Effects** Paradoxical bronchospasm – discontinue use immediately and seek medical advice. Candidiasis, hoarseness or throat irritation – relieve by rinsing throat with water.

■ **Presentations and Basic NHS Cost** Metered-Dose Aerosol supplied in a Breath-Operated Inhaler containing 200 doses. **Beclazone 50 Easi-Breathe, Beclazone 100 Easi-Breathe and Beclazone 250 Easi-Breathe Inhalers** deliver 50, 100 and 250 microgram beclomethasone dipropionate per actuation of the valve.

■ Product Licence Numbers (Cost)

Beclazone 50 Easi-Breathe Inhaler

PL 0530/0451 (£4.34)

Beclazone 100 Easi-Breathe Inhaler

PL 0530/0452 (£8.24)

Beclazone 250 Easi-Breathe Inhaler

PL 0530/0453 (£18.02)

■ Legal Category POM

■ **Further Information** is available on request from: Baker Norton Gemini House, Flex Meadow, Harlow Essex CM19 5TJ

■ **Date of Preparation** March 1995

Beclazone, Beclazone Easi-Breathe and Baker Norton are trademarks of Norton Healthcare Limited.

References:

- 1 Lindgren S, Bake B, Larsson S. *Eur J Respir Dis* 1987;**70**:93-98
- 2 Crompton G.K. *Eur J Respir Dis* 1982;**63**(Suppl. 119):101-104
- 3 Goodman D.E. et al. *Am J Respir Crit Care Med* 1994;**150**:1256-1261
- 4 MIMS, February 1995
- 5 Data on file, Baker Norton

**BAKER
NORTON**

Quality medicines at sensible prices

Is *Easi-Breathe* possible? ...it is now!

...and can be used by the most asthmatic device?

Breath-operated inhalers overcome co-ordination difficulties, but at a price. So switching all your patients to automatic models, although sensible, has not been viable...

...until now!



- Beclazone *Easi-Breathe* costs the same as the standard range of Beclazone MDIs. So Beclazone *Easi-Breathe* is not only 20-22% less expensive than the originator BDP metered-dose inhalers¹, it also provides as much as a 61% saving compared to some BDP disk dry powder inhalers².
- Switching BDP inhaler patients to Beclazone *Easi-Breathe* could save the NHS a breathtaking £30 million a year³. That's an extra 1,500-2,500 extra nurses, 200,000 outpatient consultations, 10,000 hip replacements, or 30,000 cataract operations³.
- And whilst Beclazone *Easi-Breathe's* classic styling will be reassuringly familiar to patients, its remarkably easy handling will come as a pleasant surprise.
- All your patient has to do is *Open, Breathe, Close*.



Beclazone *Easi-Breathe*

Beclomethasone Dipropionate BP 50, 100 & 250 microgram inhalers

**BAKER
NORTON**

Quality medicines at sensible prices

Designed to save lives Priced to save millions

Presentations: Pulmicort Respules (2 ml single dose unit ampoules) containing 0.25 mg/ml or 0.5 mg/ml budesonide in a suspension for nebulisation. **Uses:** Bronchial asthma where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. **Dosage and administration:** Dosage schedules. Administer from suitable nebulisers. Dose delivered to the patient varies depending on the nebulising equipment used (see data sheet). Adjust dosage individually. Initially during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids the recommended dose in adults (including elderly and children 12 years and older) is usually 1-2 mg twice daily. In very severe cases the dosage may be further increased. Children 3 months to 12 years: 0.5-1 mg twice daily. The maintenance dose should be the lowest dose which keeps the patient symptom-free. Recommended doses are: Adults (including elderly and children 12 years and older): 0.5-1 mg twice daily. Children (3 months to 12 years): 0.25-0.5 mg twice daily. For an increased therapeutic effect increase dose of Pulmicort rather than combine treatment with oral corticosteroids because of the lower risk of systemic effects. **Contra-indication:** Hypersensitivity to any of the constituents. **Special warnings and precautions:** Care is needed in patients with pulmonary tuberculosis and viral infections in the airways. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive

mucus in the bronchi. Transfer of patients dependent on oral steroids to Pulmicort demands special care, see data sheet for further details. The nebuliser chamber should be cleaned and dried after every administration. Pulmicort does not affect the ability to drive and use machines. Pulmicort Respules can be mixed with 0.9% saline and with solutions of terbutaline, salbutamol, sodium cromoglycate or ipratropium bromide. **Side effects:** Mild irritation in the throat, coughing and hoarseness and oral candidiasis have been reported. In rare cases inhaled drugs may provoke bronchoconstriction in hyperreactive patients. Facial skin should be washed after use of the face mask as irritation can occur. Coughing can usually be prevented by inhaling a β_2 agonist (e.g. terbutaline) 5-10 minutes before inhalation of Pulmicort Respules. Avoid in pregnancy. **Pharmaceutical precautions:** Store below 30°C. Use within 3 months of opening the foil envelope. Protect opened ampoules from light. Use within 12 hours of opening. **Legal category:** POM. **Basic NHS price:** Pulmicort Respules 0.25 mg/ml (20 single dose units) £32.00. Pulmicort Respules 0.5 mg/ml (20 single dose units) £44.64. **Product licence numbers:** Pulmicort Respules 0.25 mg/ml PL 0017/0309. Pulmicort Respules 0.5 mg/ml PL 0017/0310. **For further information contact the product licence holder:** Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH. **Reference:** 1. Higenbottam TW et al. Eur J Clin Res 1994; 5: 1-10.



Time to take a breather from oral steroids

Pulmicort[®]
BUDESONIDE
Respules[®]

A high-dose nebulised steroid that's low on side effects^{1†}

Indications Prophylaxis and treatment of asthma.

Contraindications Hypersensitivity to fluticasone propionate or any of the excipients.

Warnings See prescribing information. Please refer to the full data sheet (before prescribing).

Uses Topically active corticosteroid for the prophylactic management of asthma.

Dosage and administration For inhalation only. Use regularly. Onset of therapeutic effect usually occurs in 7 days. *Adults:* 100 to 1,000 micrograms twice daily. *Children over 12 years:* 50 to 100 micrograms twice daily.

Contraindications Hypersensitivity.

Precautions *Severe or unstable asthma:* Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases or becomes less effective. Consider increasing oral steroids and/or increasing doses of inhaled corticosteroids. In severe exacerbations in the normal range. *Acute symptoms:* Flixotide is not for relief of acute symptoms. A short-acting inhaled bronchodilator is required. *Systemic effects:* Adrenal function and reserve usually remain within the normal range. Some systemic effects may occur in a small proportion of adults after long-term treatment at maximum recommended dose. No systemic effects have been seen in children. *Transfer from oral steroids:* Special care is needed. Monitor adrenal function. Do not stop Flixotide abruptly. Consider additional corticosteroid therapy in situations likely to produce stress. *Tuberculosis:* Special care is needed in active or quiescent pulmonary tuberculosis. *Pregnancy and lactation:* Experience is limited. Balance risks against benefits. *Side effects:* Candidiasis of mouth and throat, hoarseness. *Paradoxical bronchospasm:* Substitute alternative therapy.

Presentation and Basic NHS cost
Flixotide Inhaler: 120 actuations per inhaler. 25 micrograms - £6.86.
 50 micrograms - £11.43.
 100 micrograms - £22.86.
Flixotide Diskhaler: Pack of 14 four-place disks together with a Flixotide Diskhaler.
 25 micrograms - £8.23.
 50 micrograms - £12.80.
 100 micrograms - £24.23.
Flixotide Diskhaler refill pack: Pack of 14 four-place disks only. 50 micrograms - £7.66. 100 micrograms - £12.23.
 50 micrograms - £23.66.
 100 micrograms - £39.66.
 Hospital packs are also available.

Product licence numbers
 0949/0001, 0949/0002, 0949/0003, 0949/0004, 0949/0005, 0949/0006, 0949/0007, 0949/0008.

POM

The choice is yours




ALLEN & HANBURY'S

Further information is available on request from:
 Allen & Hanburys Limited
 Uxbridge, Middlesex UB11 1BT
 Diskhaler and Flixotide are trade marks of the Glaxo Group of Companies

January 1995


FLIXOTIDE

fluticasone propionate



Designed for control, with safety in mind.

Introducing the only metered dose inhaler that meets today's mandate.



The manufacture of aerosol inhalers containing chlorofluorocarbons (CFCs) is likely to be banned in the future, to comply with the Montreal Protocol, a world mandate to protect our environment.

New Airomir inhaler is the first ever CFC-free metered dose inhaler for asthma - and the only metered dose aerosol inhaler to meet this important initiative.

Airomir inhaler delivers salbutamol sulphate, and has comparable efficacy and safety to the brand leading CFC-salbutamol inhaler^{1,3} at a comparable price.⁴

Switch your asthmatics to Airomir inhaler today, and help make a world of difference.

ABBREVIATED PRESCRIBING INFORMATION: **Presentation:** A pressurised inhalation aerosol delivering Salbutamol Sulphate Ph Eur equivalent to salbutamol 100 mcg into the mouthpiece of the adaptor. Airomir inhaler contains a new propellant, HFA-134a, and does not contain chlorofluorocarbons (CFCs). **Indications:** For the treatment of reversible airways obstruction associated with asthma, chronic bronchitis or emphysema. It may also be used prophylactically for the treatment of exercise induced asthma. **Dosage:** *Adults and elderly:* One or two inhalations as a single dose for the relief of reversible airways obstruction associated with asthma, bronchitis or emphysema. For the prevention of exercise induced asthma, two inhalations prior to exercising. *Children:* One inhalation for the relief of asthma, increasing to two as a single dose if necessary. One inhalation prior to exercise, increasing to two if necessary. Maximum dose for all patients - eight inhalations in 24 hours. **Contra-indications:** Hypersensitivity to salbutamol or any of the inactive ingredients in the Airomir inhaler. It should not be used in the management of premature labour and threatened abortion. **Precautions:** Administer cautiously to patients with thyrotoxicosis. Potentially serious hypokalaemia has been reported in patients taking beta-2 agonist therapy. Patients should be advised to seek medical advice if treatment ceases to be effective and/or their asthma seems to be worsening. Patients should not increase the dose without seeking

medical advice. Salbutamol and non-selective beta-blockers should not usually be prescribed together. **Side-effects:** Mild tremor, headache, tachycardia, palpitations, transient muscle cramps. Paradoxical bronchospasm and potentially serious hypokalaemia have been reported in patients taking beta-2 agonists. **Pregnancy:** There is no experience of Airomir inhaler in human pregnancy. The safe use of salbutamol during pregnancy has not been established but it has been in widespread use for many years without apparent ill consequence. Studies of propellant HFA-134a in pregnant rats or rabbits have not shown any special hazard. **Lactation:** It is not known whether salbutamol or propellant HFA-134a are distributed into human breast milk. **Pharmaceutical precautions:** Store below 30°C protected from frost and direct sunlight. As the vial is pressurised no attempt should be made to puncture it or dispose of it by burning. **Basic NHS price:** £2.30. **Product licence number:** PL0068/0165. **Legal Category:** POM. **Date of preparation:** March 1995. **References:** 1. Data on file. 3M Health Care. Study 1012-SILV. 2. Data on file. 3M Health Care. Study 1037-SILV. 3. Data on file. 3M Health Care. Study 1031-SILV. 4. MIMS March 1995. **Date of preparation of literature:** March 1995. Further information is available from the 3M Health Care Information Scientist: Telephone Loughborough (01509) 611611. Pharmaceutical Division, 3M Health Care, Loughborough, England. 3M and Airomir are trademarks of the 3M Company.

New
Airomir™
(salbutamol sulphate inhaler)

The world's first CFC-free metered dose inhaler for asthma therapy

CFC FREE SYSTEM

DECISIVE ACTION

...the following Kit
...time, 50ml
...transfer
...cap
...of
...and mixed
...by ampoule
...Infusion Kit -
...time
...stration
... (See Data Sheet for details.) 1g to
... by the i.p. route
... dialysis fluid. Most
... B.i.d.; severe infections,
... per day. Cystic fibrosis - up
... per day in three divided doses.
... should be reduced when
... filtration <50ml/min. An
... 1g loading dose may be given with
... renal insufficiency. **Elderly:**
... should not normally exceed
...
Neonates/Infants/Children: (See Data
... for details.) Up to two months: 25
... 60mg/kg/day as two divided doses.
... Over two months: 30 to 100mg/kg/day as
... two or three divided doses. Cystic
... fibrosis, meningitis, immunocompromised:
... up to 150mg/kg/day (max 6g daily) in
... three divided doses. Sensitivity results
... are recommended before commencing
... meningitis monotherapy. The Infusion
... Kit, in the dosage presented, may not be
... appropriate for use in children.

Contra-indication Known
... hypersensitivity to cephalosporins.

Precautions Previous anaphylactic
... reaction to penicillin. Administer with
... caution in early pregnancy, infancy and
... with concurrent nephrotoxic drug
... treatment. Fortum is excreted in
... human milk in low concentrations.
... Slight interference with copper
... reduction methods may occur.
... Fortum and aminoglycosides
... should not be mixed in
... the same giving set or
... syringe. Prolonged use
... may cause overgrowth
... of non-susceptible
... organisms (e.g.
... Candida,
... Enterococci)

... which may require
... interruption of treatment
... or other measures. **Side effects**
... Adverse reactions occur infrequently;
... pain and/or inflammation (i.m.) and
... phlebitis and/or thrombophlebitis (i.v.),
... rashes, fever, pruritus, anaphylaxis, GI
... disturbances, headache, dizziness,
... paraesthesia and bad taste. Transient
... changes in laboratory values may occur:
... eosinophilia, positive Coombs' test,
... thrombocytosis, leucopenia, neutropenia,
... thrombocytopenia and slight rises in
... hepatic enzymes. **Basic NHS cost** Packs
... of vials for injection (5 x 250mg, 5 x
... 500mg, 5 x 1g, 5 x 2g), and an infusion
... pack (5 x 2g); £9-90 per gram.
... Fortum/Saline Infusion Kit; £20-82.

Product licence numbers Fortum for
... injection: 250mg: 0004/0304; 500mg:
... 0004/0292; 1g: 0004/0293; 2g: 0004/0294.
... Sodium Chloride Intravenous Infusion:
... 3460/0015. **Product licence holder**
... Fortum for Injection: Glaxo Operat
... UK Limited, Greenford, Middlesex
... UB6 0UE. Sodium Chloride In
... venous Infusion: Galen Research Ltd, Craigavon,
... Northern Ireland BT63 5UA. **POM**

Glaxo

Further information is available on request
from: Glaxo Laboratories Limited,
Stuckley Park West, Uxbridge, Middlesex
UB11 1BT Tel: 061-950 9444.
Fortum is a Glaxo trade mark.

December 1993

Programme in cut



FORTUM

ceftazidime

... in serious infections

TAKE THE STRAIN OUT OF PNEUMONIA



Once an X-ray confirms your diagnosis of pneumonia you need to act quickly. Treatment with once a day ROCEPHIN can be started immediately, before the results of susceptibility tests are known.

With a clinical success rate of 89.7% (n=1,060),^{1,2} ROCEPHIN provides effective treatment of pneumonia, with proven efficacy in both community acquired and nosocomial pneumonia.³

Once-a-day

▼ Rocephin[®]
ceftriaxone

THE WORLD'S BEST SELLING
INJECTABLE ANTIBIOTIC⁴

References

1. Brown, F.B. and Sands, M. *Curr. Ther. Res.* (1989), **46** (2), 285-91.
2. Data On File. (GCR B-116 232). 3. Niebuhr, H. *et al.* *Chemotherapie Journal* (1993), **2**, 28-35. 4. Estimated current cash annual sales worldwide - Data on File. Roche Products Ltd.

Brief Prescribing Information

Indications: Pneumonia, septicaemia; meningitis; bone, skin and soft tissue infections; infections in neutropenic patients; gonorrhoea; peri-operative prophylaxis of infections associated with surgery. Treatment may be started before the results of susceptibility tests are known. **Dosage and Administration:** Rocephin should be administered by deep intramuscular injection, slow intravenous injection, or as a slow intravenous infusion after reconstitution of the solution. **Adults and children 12 years and over:** Standard dosage - 1g once daily. Severe infections - 2-4g normally once daily. Duration of therapy varies according to course of disease. Gonorrhoea - single dose of 250mg i.m. Peri-operative prophylaxis - usually single dose of 1g, colorectal surgery 2g in conjunction with a suitable agent against anaerobic bacteria. **Children under 12 years:** Standard dosage - 20-50mg/kg once daily. Severe infections - maximum 80mg/kg once daily. Doses of 50mg/kg or over should be given by slow intravenous infusion over

at least 30 minutes. **Renal and hepatic impairment:** In the absence of hepatic impairment dose reduction is required only in severe renal failure (creatinine clearance <10ml/min), when the daily dose should be 2g or less. No dose reduction is required in liver damage provided renal function is intact. In severe renal impairment accompanied by hepatic insufficiency the plasma concentration should be determined at regular intervals and dosage adjusted. Serum concentrations should be monitored in dialysis. **Contra-indications, Warnings etc.** Cephalosporin hypersensitivity. Premature infants. Full-term infants during first six weeks of life. Safety in pregnancy has not been established. **Precautions:** Stated dose should not be exceeded. Caution in patients with a history of hypersensitivity (especially anaphylactic reaction) to penicillins or other non-cephalosporin beta-lactam antibiotics. Anaphylactic shock requires immediate countermeasures. Severe renal impairment accompanied by hepatic insufficiency (see Dosage). **Side-effects and Adverse Reactions:** Gastro-intestinal side-effects including loose stools, diarrhoea, nausea, vomiting, stomatitis and glossitis. Cutaneous reactions including maculopapular rash, pruritus, urticaria, oedema and erythema multiforme. Haematological reactions including anaemia (all grades), leucopenia, neutropenia, thrombocytopenia, eosinophilia, agranulocytosis positive Coombs' test and

prolongation of prothrombin time. Regular blood counts should be carried out during treatment. Other reactions include headache, dizziness, drug fever and transient elevations in liver function tests. Rarely, glycosuria, oliguria, haematuria, anaphylaxis and bronchospasm. Very rarely, precipitation of ceftriaxone calcium salt in urine in patients on higher than recommended dose. Reversible precipitates of calcium ceftriaxone have been detected by gallbladder sonograms. In symptomatic cases (which are rare), conservative non-surgical management is recommended. Superinfections with yeasts, fungi or other resistant organisms. Rare instances of pseudomembranous colitis. Injection site pain and local phlebitis. **Legal Category:** POM. **Presentations and Basic NHS Cost:** 250mg vials i.m. and i.v. (containing 250mg ceftriaxone) - £2.87. 1g vials i.m. and i.v. (containing 1g ceftriaxone) - £11.46. 2g vials for infusion (containing 2g ceftriaxone) - £22.92. **Product Licence Numbers:** PL 0031 0169 (250mg vials), PL 0031 0171 (1g vials), PL 0031 0172 (2g vials). **Product Licence Holder:** Roche Products Limited, PO Box 8, Welwyn Garden City, Hertfordshire, AL7 3AY. Full prescribing information is available on request.



When knowledge is critical...

ASSISTED VENTILATION

SECOND EDITION

EDITED BY JOHN MOXHAM AND JOHN GOLDSTONE



BMJ
Publishing
Group

Thorax

...of modern
respiratory ventilation.
Now fully revised and
updated, with additional
illustrations, this second
edition includes an
expanded section on
non-invasive positive
pressure ventilation.

"An invaluable
introduction to
ventilatory
techniques".

Care of the Critically Ill

Edited by
John Moxham and
John Goldstone.

Quality and Safety in Anaesthesia



Edited by Jonathan Secker Walker

BMJ
Publishing
Group

...of the process of
quality assurance to the
drive to improve quality of
practice in anaesthesia,
addressing vital issues
such as:

- Management of risk and resources
- Standard setting in training and monitoring
- Critical incidents and human factors
- The role of computers

Edited by
Jonathan Secker Walker

ISBN 0 7279 0843 X 115 pages September 1994
UK £12.95; Overseas £14.00 (BMA members £11.95; £13.00)

ISBN 0 7279 0828 6 212 pages 1994
UK £16.95; Overseas £19.00 (BMA members £15.95; £18.00)

FROM THE PRINCIPLES IN PRACTICE SERIES:

Pulse Oximetry by John Moyle

UK £16.95; Overseas £19.00
(BMA members £15.95; £18.00)

Capnography by David O'Flaherty

UK £16.95; Overseas £19.00
(BMA members £15.95; £18.00)

ORDER FORM

Available from: BMJ Publishing Group, P.O. Box 295, London WC1H 9TE (Tel: 071 383 6185/6245), or medical booksellers.

Please send me _____ copy/ies of **Assisted Ventilation**

Please send me _____ copy/ies of **Quality and Safety in Anaesthesia**

Please send me _____ copy/ies of **Pulse Oximetry**

Please send me _____ copy/ies of **Capnography**

Name _____
(Print in Block)

Address _____

Postcode _____

BMA Membership No. _____

Cheque enclosed (made payable to British Medical Journal) £ _____
or Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. _____ Exp _____

Signature _____

Please send me a BMJ PUBLISHING GROUP CATALOGUE

BMJ
Publishing
Group



HELPING ASTHMATICS BREATHE EASY

BREATH ACTUATED

AerolinTM AutohalerTM

salbutamol breath-actuated inhaler



CONSISTENT SALBUTAMOL DELIVERY
WITH RAPID RESPONSE

AEROLINTM AUTOHALERTM INHALER ABBREVIATED PRESCRIBING INFORMATION. **Presentation:** A breath-actuated pressurised inhalation aerosol delivering Salbutamol Sulphate BP equivalent to salbutamol 100mcg into the mouthpiece of a breath-actuated adaptor. **Indications:** For the treatment of reversible airways obstruction associated with asthma. **Dosage:** *Adults and children:* one inhalation as a single dose for the relief of acute bronchospasm, increasing to two inhalations if necessary. Maximum of eight puffs in 24 hours. **Contra-indications:** Hypersensitivity to salbutamol or any of the inactive ingredients in the Aerolin Autohaler inhaler. **Precautions:** Administer cautiously to patients with thyrotoxicosis. Patients should be advised to seek medical advice if treatment ceases to be effective and/or their asthma seems to be worsening. Patients should not increase the dose without seeking medical advice. Salbutamol and non-selective beta-blockers should not usually be

prescribed together. **Side-effects:** Mild tremor, headache, tachycardia, palpitations and transient muscle cramps may rarely occur. Paradoxical bronchospasm and potentially serious hypokalaemia have been reported in patients taking B₂ agonist therapy. **Pregnancy:** The safe use of salbutamol during pregnancy has not been established. **Lactation:** It is not known whether salbutamol is distributed into breast milk. **Pharmaceutical precautions:** Store below 30°C protected from frost and direct sunlight. As the vial is pressurised no attempt should be made to puncture it or dispose of it by burning. **Basic NHS price:** £10.51. **Product licence number:** PL 68/0117. **Legal Category:** POM. Date of preparation of advertisement: February 1995. Further information is available from the 3M Health Care Information Scientist: Telephone Loughborough (01509) 611611. Pharmaceutical Division, 3M Health Care, Loughborough, England. Aerolin, Autohaler and 3M, are trade marks of the 3M company.

3M Health Care

*Now you can find the information
you really need...*






Evidence-Based Medicine

Editors: B Haynes & D Sackett

With 2 million new papers published each year how can you be sure you read all the papers essential for your daily practice, and how can you be sure of the scientific soundness of what you do read? One answer to this dilemma is practising evidence based medicine, basing clinical decisions on the best available scientific evidence.

To meet this need the BMJ Publishing Group together with the American College of Physicians is launching a new journal - *Evidence - Based Medicine*. This new journal is a development of the ACP Journal Club.

Published bi-monthly *Evidence - Based Medicine*, will survey a wide range of international medical journals (at least 50) to identify the key research papers that are scientifically valid and relevant to practice.



Launching in September 1995.
***Evidence-Based Medicine* will:**

- use scientific criteria to select the abstracts from the most important papers from the world's leading journals
- select only those papers which have a direct message for practice
- provide commentaries on the abstracts which will make clear the importance of the papers
- supply educational material to teach you about evidence based medicine
- cover all medical advances that are really important
- cover internal medicine, and the major specialties, including general surgery, paediatrics, obstetrics & gynaecology, psychiatry, general practice, anaesthesiology and ophthalmology.

ACP

Annual Subscription Rate (Volume One, 7 issues - 1995-96)
BMA Members Rate: £35, Personal Rate: £50, Institutional Rate: £80

BMJ
Publishing Group

Order Form

Evidence Based Medicine ISSN: 1557-5576 Publication: Bi-monthly
1995 Subscription Rate: £80 (institutional) £50 (personal): £35 (BMA members)

Please tick

Please enter my subscription start date:

I enclose a cheque for:

(Payable to British Medical Journal)

Please send me a sample copy

I wish to pay by credit card:

American Express/Visa (Barclaycard)/Mastercard *(Delete as appropriate)*

Card No.

Expiry date:

Signature:

(Your signature is essential when paying by credit card)

Name:

Address:

.....

..... Present Position

Please tick this box if you do not wish your data to be used for direct marketing purposes

N.B. Canadian subscribers must add 7% GST to quoted sterling price. Subscribers in Italy must add 4% to the quoted sterling price, unless they can provide an IVA registration number. Subscribers in the Irish Republic must add 21% VAT to the quoted sterling price, unless they can provide VAT registration number. Subscribers in Belgium must add 6% TVA/BTW to the quoted sterling price, unless they can provide a TVA/BTW registration number.

**Return to: BMJ Publishing Group, Journals Marketing Department, PO Box 299, London WC1H 9JP UK Tel: 0171 383 6270 Fax: 0171 383 6402 or
BMJ Publishing Group, PO Box 408, Franklin, MA 02038, USA Tel: 1-800-2-FON BMJ Fax: 1-800-2-FAX BMJ**

Statistically speaking, you're better off with a BMJ book...


NEW REVISED EDITION

Medical Statistics on Personal Computers

RA Brown, J Swanson Beck

How do you get the best out of the software available for analysing statistical data on PC's? This practical guide has been completely revised and updated and includes new chapters on survival analysis, statistical power calculations, writing up statistical analyses for medical papers, and useful notes on packages available.

UK £10.95; Overseas £13.00
(BMA members £9.95; £12.00)
 160 pages Second edition April 1994



Statistics in Practice

Sheila M Gore, Douglas G Altman

This authoritative book clearly and simply explains how to design studies, apply statistical techniques, and interpret studies using statistics.


UK £9.95; Overseas £11.00
(BMA members £7.95; £10.00) 107 pages 1982

Statistics at Square One

T D V Swinscow

The classic "beginner's guide", providing step by step instruction on the tools of the statistician such as: standard deviation, X² tests, non-parametric tests, and correlation.

UK £4.95; Overseas £6.00
(BMA members £4.45; £5.50)
 94 pages Eighth edition 1983



Statistics with Confidence

Martin J Gardner, Douglas G Altman

For everyone using statistical methods to present their findings, this book gives the reasons for using confidence intervals, followed by detailed methods of calculation, including numerous worked examples and specially compiled tables.

UK £9.95; Overseas £11.00 (BMA members £8.95; £10.00)
 156 pages 1989


Confidence Interval Analysis (CIA)

Martin J Gardner, Stephen B Gardner, Paul D Winter

This microcomputer disk with manual takes the sweat out of calculating confidence intervals. The program can be used alone or with *Statistics with Confidence*.

Software is available for IBM compatibles on either 5¼ or a 3½ inch disk.

UK £65.00 Educational establishments, research institutes, and the NHS: £45.95 (inc. VAT) 82 pages 1989



ORDER FORM BMJ Publishing Group, PO Box 295, London WC1H 9TE (Tel: 071 383 6185/6245)

Qty	Book Title	Amount

Prices include postage by air abroad Please send me a BMJ Publishing Group catalogue

Total £

Name _____

Address _____

Postcode _____

Cheque enclosed (made payable to British Medical Journal) £ _____ Membership No. _____

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Expiry Date _____

Card No. _____

Signature _____

BMJ Books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted.

BMJ
 Publishing Group

A LIFE-SAVING SYSTEM FOR ASTHMATICS



Bricanyl[®]

✘ **Turbohaler**[®]

TERBUTALINE SULPHATE

Pulmicort[®]

✘ **Turbohaler**[®] 200

BUDESONIDE

6436 MC 454
6-11-96 138445 XL



Abridged prescribing information: Presentation. Bricanyl Turbohaler. Dry powder inhaler delivering 0.5 mg terbutaline sulphate per actuation. **Uses** Relief and prevention of bronchospasm in bronchial asthma and bronchopulmonary disorders in which bronchospasm or reversible airways obstruction is a complicating factor. **Dosage and administration:** Adults and children (including elderly): One inhalation (0.5 mg) as required. Not more than 4 inhalations/day. **Contra-indications, warnings, etc:** Sensitivity to terbutaline sulphate. Precautions: Care should be taken in patients with myocardial insufficiency or thyrotoxicosis. Additional blood glucose measurements are initially recommended in diabetic patients. If treatment becomes less effective or shorter acting, the patient's general condition should be reviewed. Do not use in patients with hypertrophic cardiomyopathy. Potentially serious hypokalaemia may result from β_2 -agonist therapy. Administer with caution during the first trimester of pregnancy. Do not administer concurrently with non-selective β -blockers. Use with caution with other sympathomimetics. **Side effects:** Tremor, tonic cramp and palpitations are all characteristic of sympathomimetic amines. A few patients feel tense. **Basic NHS price:** Bricanyl Turbohaler (100 doses) £7.96. **Legal category:** POM. **Product licence number:** PL 0017/0241.

Presentations: Pulmicort Turbohaler 100. 100 μ g/puff budesonide dry powder inhaler containing 200 doses. Pulmicort Turbohaler 200. 200 μ g/puff budesonide dry powder

inhaler containing 100 doses. Pulmicort Turbohaler 400. 400 μ g/puff budesonide dry powder inhaler containing 50 doses. **Uses:** Bronchial asthma. **Dosage and administration:** Individual dose. Adults: 200-1600 μ g daily in divided doses. Children: 200-800 μ g daily in divided doses. Maintenance: Use lowest possible dose. Brush the teeth and rinse the mouth out with water at each use. **Contra-indications, warnings, etc:** Active pulmonary tuberculosis. Special care needed in patients with fungal and viral infections in the airways. Avoid administration during pregnancy. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to treatment with Pulmicort demands special care. See data sheet for further details. **Side effects:** Mild irritation of the throat, hoarseness and oral candidiasis occur in some patients. Rare cases of cataract have been reported after prolonged use of corticosteroids. **Legal category:** POM. **Basic NHS price:** Pulmicort Turbohaler 100 (200 doses) £18.50. Pulmicort Turbohaler 200 (100 doses) £18.50. Pulmicort Turbohaler 400 (50 doses) £18.50. **Product licence numbers:** Pulmicort Turbohaler 100 PL 0017/0319 (100 μ g/puff). Pulmicort Turbohaler 200 PL 0017/0272 (200 μ g/puff). Pulmicort Turbohaler 400 PL 0017/0271 (400 μ g/puff). **Further information is available**

ASTRA

Astra Pharmaceuticals

from the product licence holder; Astra Pharmaceuticals Limited, Home Park, Kings Langley, Herts WD4 8DH. ©Registered trade mark